Recep Tayyip Erdoğan University Institutional Repositorymetadata only
Real-world outcomes of CDK4/6 inhibitors in germline BRCA1/2-mutated hormone receptor-positive, HER2-negative metastatic breast cancer: Turkish oncology group (TOG) study
brca mutation, cdk4/6 inhibitors, hormone receptor-positive, metastatic breast cancer, palbociclib, real-world study, ribociclib
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 396732
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.